Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 1
1987 3
1988 6
1989 10
1990 7
1991 12
1992 11
1993 18
1994 13
1995 22
1996 30
1997 35
1998 41
1999 41
2000 53
2001 57
2002 44
2003 39
2004 57
2005 60
2006 83
2007 71
2008 75
2009 80
2010 99
2011 93
2012 109
2013 144
2014 160
2015 195
2016 186
2017 193
2018 220
2019 170
2020 77
Text availability
Article attribute
Article type
Publication date

Search Results

2,227 results
Results by year
Filters applied: . Clear all
Page 1
Early- and late-onset Alzheimer disease: Are they the same entity?
Tellechea P, Pujol N, Esteve-Belloch P, Echeveste B, García-Eulate MR, Arbizu J, Riverol M. Tellechea P, et al. Neurologia. 2018 May;33(4):244-253. doi: 10.1016/j.nrl.2015.08.002. Epub 2015 Nov 3. Neurologia. 2018. PMID: 26546285 Free article. Review. English, Spanish.
Early-onset Alzheimer disease (EOAD), which presents in patients younger than 65 years, has frequently been described as having different features from those of late-onset Alzheimer disease (LOAD). ...Alzheimer-type features will be more dense a …
Early-onset Alzheimer disease (EOAD), which presents in patients younger than 65 years, has frequently been described as havin …
Neuropathology and biochemistry of Aβ and its aggregates in Alzheimer's disease.
Thal DR, Walter J, Saido TC, Fändrich M. Thal DR, et al. Acta Neuropathol. 2015 Feb;129(2):167-82. doi: 10.1007/s00401-014-1375-y. Epub 2014 Dec 23. Acta Neuropathol. 2015. PMID: 25534025 Review.
Alzheimer's disease (AD) is characterized by β-amyloid plaques and intraneuronal τ aggregation usually associated with cerebral amyloid angiopathy (CAA). ...Thus, the inhibition of Aβ aggregation and maturation before entering the symptomatic stage of the
Alzheimer's disease (AD) is characterized by β-amyloid plaques and intraneuronal τ aggregation usually associated with
The neuropathology of chronic traumatic encephalopathy.
McKee AC, Stein TD, Kiernan PT, Alvarez VE. McKee AC, et al. Brain Pathol. 2015 May;25(3):350-64. doi: 10.1111/bpa.12248. Brain Pathol. 2015. PMID: 25904048 Free PMC article. Review.
Given the importance of sports participation and physical exercise to physical and psychological health as well as disease resilience, it is critical to identify the genetic risk factors for CTE as well as to understand how other variables, such as stress, age at ex …
Given the importance of sports participation and physical exercise to physical and psychological health as well as disease resilience …
The neuropathological diagnosis of Alzheimer's disease.
DeTure MA, Dickson DW. DeTure MA, et al. Mol Neurodegener. 2019 Aug 2;14(1):32. doi: 10.1186/s13024-019-0333-5. Mol Neurodegener. 2019. PMID: 31375134 Free PMC article. Review.
Alzheimer's disease is the most common cause of dementia globally. There remain no effective treatment options for the great majority of patients, and the primary causes of the disease are unknown except in a small number of familial cases driven by
Alzheimer's disease is the most common cause of dementia globally. There remain no effective treatment options for the
Biomarkers of agitation and aggression in Alzheimer's disease: A systematic review.
Ruthirakuhan M, Lanctôt KL, Di Scipio M, Ahmed M, Herrmann N. Ruthirakuhan M, et al. Alzheimers Dement. 2018 Oct;14(10):1344-1376. doi: 10.1016/j.jalz.2018.04.013. Epub 2018 Jun 23. Alzheimers Dement. 2018. PMID: 29940162
INTRODUCTION: Agitation is one of the most challenging neuropsychiatric symptoms to treat in Alzheimer's disease and has significant implications for patient and caregiver. ...METHODS: This systematic review aimed to summarize evidence on the association betw …
INTRODUCTION: Agitation is one of the most challenging neuropsychiatric symptoms to treat in Alzheimer's disease and ha …
Advances in the prevention of Alzheimer's disease and dementia.
Solomon A, Mangialasche F, Richard E, Andrieu S, Bennett DA, Breteler M, Fratiglioni L, Hooshmand B, Khachaturian AS, Schneider LS, Skoog I, Kivipelto M. Solomon A, et al. J Intern Med. 2014 Mar;275(3):229-50. doi: 10.1111/joim.12178. J Intern Med. 2014. PMID: 24605807 Free PMC article.
In the field of Alzheimer's disease (AD) research, it has taken almost three decades for diagnostic nomenclature to undergo major re-examination. ...RESULTS: The associations between neuropathology and cognition are still not entirely clear. In additio …
In the field of Alzheimer's disease (AD) research, it has taken almost three decades for diagnostic nomenclature to und …
Genetic Risk Factors for Alzheimer Disease: Emerging Roles of Microglia in Disease Pathomechanisms.
Takatori S, Wang W, Iguchi A, Tomita T. Takatori S, et al. Adv Exp Med Biol. 2019;1118:83-116. doi: 10.1007/978-3-030-05542-4_5. Adv Exp Med Biol. 2019. PMID: 30747419 Review.
The accumulation of aggregated amyloid β (Aβ) peptides in the brain is deeply involved in Alzheimer disease (AD) pathogenesis. ...In this chapter, we review current knowledge on genetic risk factors of AD, clarified by recent advances in genome analysis techn …
The accumulation of aggregated amyloid β (Aβ) peptides in the brain is deeply involved in Alzheimer disease (AD) pathogenesis. …
Alzheimer disease.
Calderon-Garcidueñas AL, Duyckaerts C. Calderon-Garcidueñas AL, et al. Handb Clin Neurol. 2017;145:325-337. doi: 10.1016/B978-0-12-802395-2.00023-7. Handb Clin Neurol. 2017. PMID: 28987180 Review.
Alzheimer disease neuropathology is characterized by the extracellular accumulation of Aβ peptide and intracellular aggregation of hyperphosphorylated tau. ...Granulovacuolar degeneration and perisomatic granules are also linked to Alzheimer disease
Alzheimer disease neuropathology is characterized by the extracellular accumulation of Aβ peptide and intracellular agg
Global quantitative analysis of the human brain proteome in Alzheimer's and Parkinson's Disease.
Ping L, Duong DM, Yin L, Gearing M, Lah JJ, Levey AI, Seyfried NT. Ping L, et al. Sci Data. 2018 Mar 13;5:180036. doi: 10.1038/sdata.2018.36. Sci Data. 2018. PMID: 29533394 Free PMC article.
Patients with Alzheimer's disease (AD) and Parkinson's disease (PD) often have overlap in clinical presentation and brain neuropathology suggesting that these two diseases share common underlying mechanisms. ...Ultimately, this comprehens …
Patients with Alzheimer's disease (AD) and Parkinson's disease (PD) often have overlap in clinical presen …
Clinical and cortical decline in the aphasic variant of Alzheimer's disease.
Rogalski EJ, Sridhar J, Martersteck A, Rader B, Cobia D, Arora AK, Fought AJ, Bigio EH, Weintraub S, Mesulam MM, Rademaker A. Rogalski EJ, et al. Alzheimers Dement. 2019 Apr;15(4):543-552. doi: 10.1016/j.jalz.2018.12.003. Epub 2019 Feb 11. Alzheimers Dement. 2019. PMID: 30765195 Free PMC article.
METHODS: Longitudinal quantitation of atrophy and language over 12 months was completed for PPA patients with and without positive amyloid PET (PPA(Aβ+) and PPA(Aβ-)), an imaging biomarker of underlying Alzheimer's disease. ...Clinical and anatomical progress …
METHODS: Longitudinal quantitation of atrophy and language over 12 months was completed for PPA patients with and without positive amyloid P …
2,227 results
Jump to page
Feedback